A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with histologically proven malignant melanoma (recurred or metastatic) that had progressed during or after receiving at least one cycle of a regimen containing dacarbazine or temozolomide in the advanced setting
- Measurable disease (RECIST)
- ECOG performance 0-2
- Adequate organ function
- Total bilirubin <1.5N ; ASAT and ALAT <2.5N
- Serum Creatinin < 1.5N
- ANC ≥ 1,500/mm³ (G-CSF allowed)
- Platelets ≥ 100,000/mm³
- Hb ≥ 9.0 g/dL
- Life expectancy of at least 12 weeks
- Signed Written Informed Consent
Exclusion Criteria:
- Symptomatic brain metastasis
- Previous history of treatment with taxane or platinum agent containing chemotherapy
- Previous major surgery within 2 weeks before the start of the trial, or a failure to recover from the surgery
- Previous history of other malignancies within 5 years except for cured skin basal cell carcinoma or cured in-situ cervix cancer
- Other severe medical conditions (infection, uncontrolled hypertension, heart failure, MI history within 6 months)
- Sensitivity to platinum agents or docetaxel
- Uncontrolled seizure
- Women pregnant or nursing
- Alcohol or drug abuser
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: weekly docetaxel and carboplatin
|
D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response Rate
Time Frame: every 6 weeks, up to 4 year
|
Response rate evaluation based on RECIST 1.1 confirmed by CT or MRI
|
every 6 weeks, up to 4 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
disease control rate
Time Frame: every 6 weeks, up to 4 year
|
every 6 weeks, up to 4 year
|
|
progression free survival
Time Frame: every 6 weeks, up to 4 year
|
every 6 weeks, up to 4 year
|
|
overall survival
Time Frame: every 6 weeks, up to 4 year
|
every 6 weeks, up to 4 year
|
|
adverse events
Time Frame: every 6 weeks, up to 4 year
|
every 6 weeks, up to 4 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Carboplatin
Other Study ID Numbers
Other Study ID Numbers
- 4-2011-0300
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.